MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 59 filers reported holding MEREO BIOPHARMA GROUP PLC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,500,125 | -2.3% | 7,364,438 | 0.0% | 0.51% | -1.3% |
| Q2 2023 | $9,721,058 | +86.7% | 7,364,438 | 0.0% | 0.52% | +136.4% |
| Q1 2023 | $5,205,921 | -5.7% | 7,364,438 | 0.0% | 0.22% | -5.2% |
| Q4 2022 | $5,523,329 | -12.9% | 7,364,438 | 0.0% | 0.23% | -11.8% |
| Q3 2022 | $6,342,000 | -38.1% | 7,364,438 | -19.4% | 0.26% | -32.4% |
| Q2 2022 | $10,239,000 | 0.0% | 9,142,067 | 0.0% | 0.39% | +24.3% |
| Q1 2022 | $10,239,000 | -30.0% | 9,142,067 | 0.0% | 0.31% | +10.6% |
| Q4 2021 | $14,627,000 | -33.9% | 9,142,067 | 0.0% | 0.28% | -24.1% |
| Q3 2021 | $22,124,000 | -19.3% | 9,142,067 | +5.7% | 0.37% | -9.0% |
| Q2 2021 | $27,418,000 | +27.8% | 8,649,300 | +35.9% | 0.41% | +29.3% |
| Q1 2021 | $21,452,000 | +118.0% | 6,365,500 | +131.6% | 0.32% | +124.8% |
| Q4 2020 | $9,841,000 | – | 2,748,999 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,854,278 | $6,638,000 | 3.61% |
| Asymmetry Capital Management, L.P. | 739,812 | $2,649,000 | 1.21% |
| Affinity Asset Advisors, LLC | 625,000 | $2,238,000 | 1.19% |
| Tri Locum Partners LP | 728,710 | $2,609,000 | 0.95% |
| Boxer Capital, LLC | 6,226,673 | $22,291,000 | 0.72% |
| DAFNA Capital Management LLC | 668,148 | $2,392,000 | 0.71% |
| Vivo Capital, LLC | 4,220,938 | $15,111,000 | 0.67% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $919,000 | 0.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 280,000 | $1,002,000 | 0.58% |
| Rubric Capital Management LP | 1,853,417 | $6,635,000 | 0.49% |